Similarly, in the ovarian cancer patients receiving taxol adjuvant therapy, the elevated mRNA levels detected by probes for DGKH (except probes 235952_at and 240145_at), FBXL7, and MFSD6 appeared to be correlated with poor outcomes (Figure 3D). The gene discussed is DGKH; the disease is ovarian carcinoma.